| (AstraZeneca) D933RC00002 / NIAGARA-2 | A Phase IIIb, Open-label, Single-arm, Global Study of Perioperative Durvalumab With Neoadjuvant ddMVAC or Gem/Cis in Patients With Muscle-Invasive Bladder Cancer | Dr Aly-Khan Lalani | Open to recruitment | NCT06960577 |
| (Bayer) 22049 / PAnTHA study | A Phase 1 open-label, first-in-human, multi-center study to evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of 225Ac-PSMA-Trillium in participants with advanced metastatic castration-resistant prostate cancer (mCRPC) | Dr Sebastien Hotte | Open to recruitment | NCT06217822 |
| (CCTG) PR.26 / TRIPLE-SWITCH | A Randomized Phase III Clinical Trial for the Addition of Docetaxel to Androgen Receptor Pathway Inhibitors in Patients with Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response (TRIPLE-SWITCH) | Dr Sebastien Hotte | Suspended/On hold | NCT06592924 |
| (Novartis) CAAA617A12402 / VISION | A Phase IV, Post-Authorization Safety Study to Investigate the Long-Term Safety of lutetium (177Lu) vipivotide tetraxetan in Adult Participants with Prostate Cancer | Dr Sebastien Hotte | Open to recruitment | NCT05803941 |
| (POINT Biopharma) PSMA-62-01 / ACCEL | [(A)c-225]-PSMA-62 Phase I/II (C)linical Trial to (C)haracterize (E)fficacy, Safety, To(L)erability, and Dosimetry in Biochemically Recurrent and Metastatic Castration Resistant Prostate Cancer (ACCEL) | Dr Sebastien Hotte | Suspended/On hold | NCT06229366 |
| (SHSC) AQuOS-II | Assessment of Quality of Life and Outcomes in Patients Treated With Stereotactic Body Radiotherapy (SBRT) for Inoperable Renal Cell Carcinoma (RCC): A Multicenter Phase II Study | Dr Anand Swaminath | Open to recruitment | NCT05023265 |
| NRG-GU010 / GUIDANCE | Parallel Phase III Randomized Trials of Genomic-Risk Stratified Unfavorable Intermediate Risk Prostate Cancer: De-Intensification and Intensification Clinical Trial Evaluation (GUIDANCE) | Dr Theos Tsakiridis | Open to recruitment | NCT05050084 |
Find a Trial
Contact Us